ATE454153T1 - 5-ht4 antagonisten zur behandlung von herzversagen - Google Patents
5-ht4 antagonisten zur behandlung von herzversagenInfo
- Publication number
- ATE454153T1 ATE454153T1 AT03725415T AT03725415T ATE454153T1 AT E454153 T1 ATE454153 T1 AT E454153T1 AT 03725415 T AT03725415 T AT 03725415T AT 03725415 T AT03725415 T AT 03725415T AT E454153 T1 ATE454153 T1 AT E454153T1
- Authority
- AT
- Austria
- Prior art keywords
- heart failure
- antagonists
- treatment
- heart
- treating
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 6
- 239000003523 serotonin 4 antagonist Substances 0.000 title abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatment Of Sludge (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211230.8A GB0211230D0 (en) | 2002-05-16 | 2002-05-16 | Treatment of heart failure |
| PCT/GB2003/002134 WO2003097065A1 (en) | 2002-05-16 | 2003-05-16 | 5-ht4 receptor antagonists for the treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454153T1 true ATE454153T1 (de) | 2010-01-15 |
Family
ID=9936797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03725415T ATE454153T1 (de) | 2002-05-16 | 2003-05-16 | 5-ht4 antagonisten zur behandlung von herzversagen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20060094715A1 (de) |
| EP (1) | EP1503764B1 (de) |
| AT (1) | ATE454153T1 (de) |
| AU (2) | AU2003227949B2 (de) |
| CA (1) | CA2485600C (de) |
| DE (1) | DE60330857D1 (de) |
| DK (1) | DK1503764T3 (de) |
| ES (1) | ES2339234T3 (de) |
| GB (1) | GB0211230D0 (de) |
| WO (1) | WO2003097065A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6278472B2 (ja) | 2013-02-27 | 2018-02-14 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体 |
| US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| WO2015134503A1 (en) * | 2014-03-04 | 2015-09-11 | The Children's Hospital Of Philadelphia | Methods for managing care of patients predisposed to progressive mitral valve diseases |
| CN109562096A (zh) * | 2016-04-13 | 2019-04-02 | 内布拉斯加大学董事会 | 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法 |
| CN113286585B (zh) * | 2019-09-20 | 2022-11-08 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018002B1 (de) | 1979-04-24 | 1983-02-09 | Marcel Jozefonvicz | Neues Bestimmungsverfahren für Proteasen und Antiproteasen |
| US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
| DE3688296T2 (de) | 1985-03-14 | 1993-11-04 | Beecham Group Plc | Arzneimittel zur behandlung von erbrechen. |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| IL87674A (en) | 1987-09-08 | 1993-08-18 | Lilly Co Eli | Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them |
| CA1317940C (en) | 1987-09-25 | 1993-05-18 | Georges H. P. Van Daele | Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| NZ227394A (en) | 1987-12-24 | 1992-04-28 | Duphar Int Res | Preparation of optically active alcohols |
| US4859683A (en) * | 1988-02-04 | 1989-08-22 | Rorer Pharmaceutical Corporation | Certain benzoxepins and their pharmaceutical compositions and methods |
| JP2643274B2 (ja) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | イミダゾ〔１，２−ａ〕ピリジン誘導体 |
| EP0387431A1 (de) | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Imidazolderivate, Verfahren zu deren Herstellung und deren Anwendung als pharmazeutische Mittel |
| IE902465A1 (en) | 1989-07-07 | 1991-02-13 | Schering Corp | Pharmaceutically active compounds |
| GB9009389D0 (en) * | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
| GB9103862D0 (en) | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| US5219850A (en) * | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5196547A (en) * | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| WO1993002677A1 (en) | 1991-08-03 | 1993-02-18 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| AU2435092A (en) | 1991-08-20 | 1993-03-16 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| US5552398A (en) | 1991-09-12 | 1996-09-03 | Smithkline Beecham P.L.C. | Azabicyclic compounds as 5-HT4 receptor antagonists |
| FI941178L (fi) | 1991-09-12 | 1994-03-11 | Smithkline Beecham Plc | 5-HT4-reseptoriantagonisteja |
| GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
| US20020128172A1 (en) * | 1991-12-21 | 2002-09-12 | Smithkline Beecham Plc | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
| US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
| WO1994008994A1 (en) | 1992-10-13 | 1994-04-28 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
| US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| CA2131797C (en) | 1992-03-12 | 2010-05-18 | Laramie Mary Gaster | Condensed indole derivatives as 5ht4-receptor antagonists |
| GB9219163D0 (en) | 1992-09-10 | 1992-10-28 | Smithkline Beecham Plc | Pharmaceuticals |
| MX9305947A (es) | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
| GB9221468D0 (en) | 1992-10-13 | 1992-11-25 | Smithkline Beecham Plc | Pharmaceuticals |
| MX9306311A (es) | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
| US5726187A (en) * | 1992-10-16 | 1998-03-10 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists |
| WO1994010174A1 (en) | 1992-11-05 | 1994-05-11 | Smithkline Beecham Plc | Piperidine derivatives as 5-ht4 receptor antagonists |
| US5472866A (en) * | 1992-12-24 | 1995-12-05 | Synaptic Pharmaceutical Corporation | DNA encoding 5-HT4A serotonin receptors |
| GB9301660D0 (en) | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
| US6127379A (en) * | 1993-02-01 | 2000-10-03 | Smithkline Beecham P.L.C. | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
| GB9310582D0 (en) * | 1993-05-22 | 1993-07-07 | Smithkline Beecham Plc | Pharmaceuticals |
| TW282460B (de) | 1993-12-28 | 1996-08-01 | Yamanouchi Pharma Co Ltd | |
| EP0774460A1 (de) | 1994-03-30 | 1997-05-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzosäurederivate und ihre medizinische verwendung |
| JPH07302236A (ja) * | 1994-05-06 | 1995-11-14 | Hitachi Ltd | 情報処理システムおよびその方法並びに情報処理システムにおけるサービス提供方法 |
| WO1995032965A1 (en) | 1994-06-01 | 1995-12-07 | Yamanouchi Pharmaceutical Co. Ltd. | Oxadiazole derivative and medicinal composition thereof |
| AU3192295A (en) | 1994-08-11 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition containing the same |
| AU3881695A (en) * | 1994-11-21 | 1996-06-17 | Asahi Kasei Kogyo Kabushiki Kaisha | Curable resin and composition |
| ES2103675B1 (es) | 1995-01-10 | 1998-07-01 | Almirall Lab | Nuevas piperidinas sustituidas. |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| JPH0967347A (ja) | 1995-08-30 | 1997-03-11 | Dainippon Pharmaceut Co Ltd | 環状アミン誘導体及びそれを含有する医薬組成物 |
| BR9611311A (pt) * | 1995-11-09 | 1999-06-29 | Synthelabo | Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 |
| JP2000504014A (ja) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| CA2237582C (en) * | 1996-02-15 | 2009-04-14 | Janssen Pharmaceutica N.V. | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| EP0944388A4 (de) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | Hemmern von farnesyl protein transferase |
| KR100494278B1 (ko) | 1996-08-16 | 2005-06-13 | 스미스클라인비이참피이엘시이 | Ｎ-[(1-ｎ-부틸-4-피페리딜)메틸]-3,4-디히드로-2Ｈ-[1,3]옥사지노[3,2-ａ] 인돌-10-카르복사미드 및 그의 염의 제조방법 및 그의 제조 중간체 |
| FR2752736B1 (fr) | 1996-08-30 | 1998-10-23 | Chu Rouen | Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides |
| GB9618967D0 (en) * | 1996-09-11 | 1996-10-23 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH10203987A (ja) | 1997-01-28 | 1998-08-04 | Dainippon Pharmaceut Co Ltd | （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤 |
| FR2762316B1 (fr) * | 1997-04-18 | 1999-12-17 | Sanofi Synthelabo | Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| CN1303376A (zh) | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9815481D0 (en) | 1998-07-16 | 1998-09-16 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9815483D0 (en) | 1998-07-16 | 1998-09-16 | Smithkline Beecham Plc | Pharmaceuticals |
| US20020091271A1 (en) * | 1998-07-16 | 2002-07-11 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| WO2001016045A1 (en) * | 1999-08-27 | 2001-03-08 | Qingdao Synergy Technology Appliance Co., Ltd. | The method for manufacturing vacuum glazing and its application mechanical system |
| BR0113073A (pt) * | 2000-08-07 | 2004-06-22 | Glaxosmithkline Lab Sas | Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial |
| CA2418921C (en) | 2000-08-08 | 2010-10-26 | Smithkline Beecham P.L.C. | Novel composition |
| NZ535261A (en) * | 2000-08-08 | 2004-12-24 | Smithkline Beecham P | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide |
| JP2005526003A (ja) * | 2001-10-22 | 2005-09-02 | ファイザー株式会社 | ５−ｈｔ４受容体調節剤としてのイミダゾピリジン化合物 |
| US6624162B2 (en) * | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| ATE329581T1 (de) | 2002-02-14 | 2006-07-15 | Glaxo Group Ltd | Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| WO2004104577A2 (en) | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4) |
| ATE539077T1 (de) | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
| DK1701951T3 (da) | 2003-12-23 | 2010-06-07 | Serodus As | Modulatorer af perifere 5-HT receptorer |
| WO2005068461A1 (en) | 2004-01-07 | 2005-07-28 | Aryx Therapeutics | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| WO2006038351A1 (ja) * | 2004-09-30 | 2006-04-13 | Sharp Kabushiki Kaisha | 結晶質半導体膜およびその製造方法 |
| EP1902044A1 (de) | 2005-07-07 | 2008-03-26 | Bio Medisinsk Innovasjon AS | 5-htx-modulatoren |
| ATE449092T1 (de) | 2005-07-22 | 2009-12-15 | Pfizer | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors |
| US20080085915A1 (en) | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
-
2002
- 2002-05-16 GB GBGB0211230.8A patent/GB0211230D0/en not_active Ceased
-
2003
- 2003-05-16 AU AU2003227949A patent/AU2003227949B2/en not_active Ceased
- 2003-05-16 US US10/514,386 patent/US20060094715A1/en not_active Abandoned
- 2003-05-16 AT AT03725415T patent/ATE454153T1/de active
- 2003-05-16 EP EP03725415A patent/EP1503764B1/de not_active Expired - Lifetime
- 2003-05-16 WO PCT/GB2003/002134 patent/WO2003097065A1/en not_active Ceased
- 2003-05-16 DK DK03725415.8T patent/DK1503764T3/da active
- 2003-05-16 ES ES03725415T patent/ES2339234T3/es not_active Expired - Lifetime
- 2003-05-16 CA CA2485600A patent/CA2485600C/en not_active Expired - Fee Related
- 2003-05-16 DE DE60330857T patent/DE60330857D1/de not_active Expired - Lifetime
-
2009
- 2009-01-06 AU AU2009200050A patent/AU2009200050B2/en not_active Ceased
- 2009-02-17 US US12/372,592 patent/US8829028B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503764B1 (de) | 2010-01-06 |
| US20060094715A1 (en) | 2006-05-04 |
| US8829028B2 (en) | 2014-09-09 |
| AU2009200050A1 (en) | 2009-02-05 |
| HK1072012A1 (en) | 2005-08-12 |
| AU2009200050B2 (en) | 2010-11-11 |
| DK1503764T3 (da) | 2010-05-10 |
| CA2485600A1 (en) | 2003-11-27 |
| AU2003227949A1 (en) | 2003-12-02 |
| AU2003227949B2 (en) | 2008-12-11 |
| ES2339234T3 (es) | 2010-05-18 |
| GB0211230D0 (en) | 2002-06-26 |
| CA2485600C (en) | 2010-04-20 |
| WO2003097065A1 (en) | 2003-11-27 |
| EP1503764A1 (de) | 2005-02-09 |
| DE60330857D1 (de) | 2010-02-25 |
| US20090169545A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| TNSN07376A1 (en) | Npy antagonists, preparation and use | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| TW200510416A (en) | P38 inhibitors and methods of use thereof | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
| MX2007002311A (es) | Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos. | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
| ATE465735T1 (de) | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| ATE454153T1 (de) | 5-ht4 antagonisten zur behandlung von herzversagen | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1503764 Country of ref document: EP |